BACKGROUND/AIM: We previously reported the usefulness of aberrant methylation of tumor suppressive miRNAs in bile to discriminate pancreaticobiliary cancers (PBCs) from benign pancreaticobiliary diseases (BD). Here we performed a methylation analysis of plasma miRNAs to identify miRNAs specific for PBCs. PATIENTS AND METHODS: Plasma was collected from 80 patients with pancreatic cancer (PC); 18 with biliary tract cancer (BTC) and 28 with BD. Sequences encoding 3 tumor suppressive miRNAs (miR-200a, -200b, and -1247) were PCR amplified and sequenced, and their methylation rates were determined. RESULTS: The methylation rate of miR-1247 was significantly higher in patients with BTC than in those with BD, and tended to be higher in patients with PC than in those with BD. Furthermore, it was significantly higher in three patients with stages I/II BTC than in those with BD. CONCLUSION: Methylation of miR-1247 in plasma may be useful to distinguish BTC from BD. Copyright 2022, International Institute of Anticancer Research.
BACKGROUND/AIM: We previously reported the usefulness of aberrant methylation of tumor suppressive miRNAs in bile to discriminate pancreaticobiliary cancers (PBCs) from benign pancreaticobiliary diseases (BD). Here we performed a methylation analysis of plasma miRNAs to identify miRNAs specific for PBCs. PATIENTS AND METHODS: Plasma was collected from 80 patients with pancreatic cancer (PC); 18 with biliary tract cancer (BTC) and 28 with BD. Sequences encoding 3 tumor suppressive miRNAs (miR-200a, -200b, and -1247) were PCR amplified and sequenced, and their methylation rates were determined. RESULTS: The methylation rate of miR-1247 was significantly higher in patients with BTC than in those with BD, and tended to be higher in patients with PC than in those with BD. Furthermore, it was significantly higher in three patients with stages I/II BTC than in those with BD. CONCLUSION: Methylation of miR-1247 in plasma may be useful to distinguish BTC from BD. Copyright 2022, International Institute of Anticancer Research.
Authors: Jong Y Park; James Helm; Domenico Coppola; Donghwa Kim; Mokenge Malafa; Seung Joon Kim Journal: World J Gastroenterol Date: 2011-02-21 Impact factor: 5.742
Authors: Ang Li; Jun Yu; Haeryoung Kim; Christopher L Wolfgang; Marcia Irene Canto; Ralph H Hruban; Michael Goggins Journal: Clin Cancer Res Date: 2013-05-22 Impact factor: 12.531
Authors: Torsten Voigtländer; Shashi K Gupta; Sabrina Thum; Jasmin Fendrich; Michael P Manns; Tim O Lankisch; Thomas Thum Journal: PLoS One Date: 2015-10-02 Impact factor: 3.240
Authors: Christian Mayr; Marlena Beyreis; Andrej Wagner; Martin Pichler; Daniel Neureiter; Tobias Kiesslich Journal: Biomed Res Int Date: 2016-11-09 Impact factor: 3.411